Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) through its wholly owned subsidiary MindWave Innovations Inc., is featured in the latest CryptoCurrencyWire Audio Production released by IBN. During the interview with IBN’s Carmel Fisher, MindWave CEO Dr. Vin Menon discusses the development of MindChain, an institutional blockchain platform designed to combine digital asset infrastructure with insurance […]

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.  MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) announced that GLJ Ltd., working with the company’s geological team, has identified evidence of a deep conduit near Lawson 4 at its Lawson Natural Hydrogen Complex in Saskatchewan. The findings, […]

Most recovery drinks promise relief after a night out, yet few have been tested against a placebo in a registered human trial. One that has is now getting a close look from a major fitness publication. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative, metabolic and alcohol misuse disorders, has invented unbuzzd, […]

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac monitoring and detection, announced positive results from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment. The findings were presented at the Transcatheter Cardiovascular Therapeutics (“TCT”) 2026 conference in San Diego. The study enrolled 132 adults and compared HeartBeam’s portable, cable-free electrocardiogram […]

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. Satellite navigation used to be something militaries could count on without a second thought. That assumption is gone. GPS signals are now routinely jammed or spoofed in active conflict zones, and uncrewed systems that depend on them can lose […]

Shooters may spend thousands on their guns, optics, ammunition, and eyewear, yet often protect their hearing with only a few cents’ worth of foam. The same gap between investment and protection shows up wherever people work or train in loud environments, from firing ranges and hunting grounds to factory floors. Silynxcom (NYSE American: SYNX), a […]

Wrap Technologies (NASDAQ: WRAP), a provider of non-lethal response technologies and public safety solutions, announced the appointment of former New York City Police Department Deputy Commissioner Edward Delatorre Jr. to its board of directors, effective Oct. 20, 2026. Delatorre brings 46 years of law enforcement experience, including leadership roles as NYPD chief of transit, commanding officer […]

Wrap Technologies (NASDAQ: WRAP) is expanding its public safety technology strategy by connecting remote restraint, scenario-based training, evidence management and emerging threat-detection systems into a more integrated offering. Its portfolio includes the BolaWrap 150 restraint device, WRAP Reality virtual reality training simulator and WrapShield platform, which initially focuses on detecting and responding to unmanned aircraft […]

REV (TSX.V: REVX) (OTCID: REVFF) announced the identification of highly elevated helium concentrations across multiple geological horizons during its maiden drilling program at the Aden Dome Property along the Alberta-Montana border. Geophysical logs also indicated exceptional reservoir properties, supporting the potential for a new helium discovery in the Sweet Grass Corridor. The company has contracted […]

VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (“NAMs”), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC(R) […]

Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (“MS”). Following U.S. Food and Drug Administration clearance of its Investigational New Drug application in August 2026, the agreement moves the […]

Hydrofarm (NASDAQ: HYFM) announced the closing of its previously disclosed registered direct offering of 1,599,400 common shares at $0.905 per share and concurrent private placement of 7,611,575 unregistered common shares or pre-funded warrants and 9,210,975 common stock purchase warrants. The transactions generated approximately $8.3 million in gross proceeds before fees and expenses. Chairman and CEO […]